Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
Explore our sectors
Meet our lawyers
News and insights
News: 29 September 2023
Allen & Overy advises on financing for Cinven’s takeover offer for Synlab
Allen & Overy (A&O) has advised 15 bank underwriters (Barclays Bank, BNP Paribas, Citibank, Crédit Agricole Corporate and Investment Bank, Deutsche Bank, Mizuho Bank, Natixis, Banco Santander, Goldman…
Blog Post: 17 July 2023
When is the composition of a product on the market prior art?
G1/23 – EPO Enlarged Board of Appeals of the EPO “available” (referral from T 0438/19) Under which circumstances can the public prior use of a product constitute prior art for novelty or inventive…
Blog Post: 04 May 2023
Podcast: Scaling up science - how to grow your life sciences venture
How and when do life sciences entrepreneurs decide whether to raise more funds, partner with big pharma, or exit their company? What strategies and tactics do they apply? And what are the key lessons…
Blog Post: 23 March 2022
New decisions in Europe and the US in CRISPR/Cas9 patent dispute
CRISPR/Cas technology, also known as “genetic scissor”, is one of the most targeted and promising tools in gene technology. It allows targeted and extremely precise modification of the DNA in humans,…